Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: Low donor chimerism predicts for poor response

Vanstraelen, Gaëtan; Baron, Frédéric; Willems, Évelyne; Bonnet, Christophe; Hafraoui, Kaoutar; Frère, Pascale; Fillet, Georges; Béguin, Yves

doi:10.1016/j.exphem.2006.04.012

Cited by 8 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 We also carried out a pilot trial of rhEPO therapy in patients undergoing NMHCT. 15 A first group started rhEPO on D0 and a second started on D28 after transplantation. Compared with historical controls, Hb values were higher but transfusion requirements were decreased only in the first month in patients receiving rhEPO from D0.…”

Section: Introductionmentioning

confidence: 99%

“…Hence, we had 3 cohorts: the first cohort included patients undergoing MA HCT with rhEPO to be started on D28, the second cohort patients given NMHCT with rhEPO to be started on D28, and the third cohort patients undergoing NMHCT with rhEPO to be started on D0. Based on our pilot studies in the MA 13 and non-MA 15 settings, we calculated that we needed 118 evaluable patients to have a 90% power to detect a significance level of 0.05, a difference in the primary end points of 75%, 50%, and 45% in the MA, non-MA D28, and nonmyeloablative D0 cohorts, respectively. The study started with the first 2 cohorts only, to which patients were assigned on the basis of their conditioning (MA vs non-MA), all starting rhEPO on D28.…”

Section: Introductionmentioning

confidence: 99%

“…The study started with the first 2 cohorts only, to which patients were assigned on the basis of their conditioning (MA vs non-MA), all starting rhEPO on D28. When the results of our pilot rhEPO trial after NMHCT became available, 15 we added through an amendment the third cohort (NMHCT with rhEPO from D0) that was scheduled to start only when recruitment in cohort 2 (NMHCT with rhEPO from D28) was completed. Study procedures remained otherwise identical.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial

Jaspers

Baron

Willems

et al. 2014

Blood

Self Cite

View full text Add to dashboard Cite

Key Points• Erythropoietin therapy can be effective to hasten erythroid recovery and reduce transfusion requirements after allogeneic HCT.We conducted a prospective randomized trial to assess hemoglobin (Hb) response to recombinant human erythropoietin (rhEPO) therapy after hematopoietic cell transplantation (HCT). Patients (N 5 131) were randomized (1:1) between no treatment (control arm) or erythropoietin at 500 U/kg per week (EPO arm). Patients were also stratified into 3 cohorts: patients undergoing myeloablative HCT with rhEPO to start on day (D)28, patients given nonmyeloablative HCT (NMHCT) with rhEPO to start on D28, and patients also given NMHCT but with rhEPO to start on D0. The proportion of complete correctors (ie, Hb ‡13 g/dL) before D126 posttransplant was 8.1% in the control arm (median not reached) and 63.1% in the EPO arm (median, 90 days) (P < .001). Hb levels were higher and transfusion requirements decreased (P < .001) in the EPO arm, but not during the first month in the nonmyeloablative cohort starting rhEPO on D0. There was no difference in rates of thromboembolic events or other complications between the 2 arms. This is the first randomized trial to demonstrate that rhEPO therapy hastens erythroid recovery and decreases transfusion requirements when started one month after allogeneic HCT. There was no benefit to start rhEPO earlier after NMHCT. (Blood. 2014;124(1):33-41)

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial

Jaspers

Baron

Willems

et al. 2014

Blood

Self Cite

View full text Add to dashboard Cite

show abstract

“…17 Two recent studies have investigated the use of Epo after nonmyeloablative conditioning or RIC. 35,36 Ivanov et al 35 gave Epo (either 30 000 IU epoetin-beta or 150 mg darbepoetinealpha per week, started on day 1) to 20 consecutive patients following RIC allogeneic HCT (Epo group). Conditioning combined fludarabine, busulfan and ATG.…”

mentioning

confidence: 99%

“…36 Fourteen patients did not receive Epo (control group), 19 were given Epo from day 0 after HCT (Epo group 1), whereas 27 were scheduled to start Epo on day 28 after HCT (Epo group 2). Recombinant human Epo was administered subcutaneously at a dose of 500 U/kg/week, with the aim of achieving Hb levels of 13 g/dl.…”

mentioning

confidence: 99%